Keyword: Foundation Medicine
Roche’s VP of global oncology strategy, Cindy Perettie, will become the next CEO of Foundation Medicine, which it acquired last year for $2.4 billion.
BMS and Eisai spinoff H3 Biomedicine will conduct research aimed at developing immune therapies for cancer using the latter’s RNA-splicing platform.
Jason Ryan has hopped from Foundation to Medicine to Magenta Therapeutics after playing a key role in Foundation’s $2.4 billion buyout by Roche.
Novartis has tapped Foundation Medicine to develop companion diagnostic tests for its cancer treatment portfolio.
Roche and Foundation Medicine launched a blood test, analyzing 70 genes known to drive solid tumor growth, to guide precision cancer treatments.
Third Rock Ventures has named Steven Kafka, former president and chief operating officer of Foundation Medicine, as a new venture partner.
The deal will further Roche’s precision medicine plans while allowing Foundation to retain autonomy and continue to work with other biopharmas.
Merck paired up with Foundation Medicine to develop a pan-cancer diagnostic for Keytruda to measure microsatellite instability and other biomarkers.
Bristol-Myers Squibb and Flatiron Health signed a three-year agreement, planning to form an advisory board on real-world evidence in drug submissions.
The alliance will see Foundation Medicine use pan-cancer test FoundationOne CDx as a companion diagnostic for Pfizer drugs.